Invokana lawsuits have taken off over the past few months and now two plaintiffs have asked for a consolidation of cases to help speed up the resolution. Invokana lawsuits allege the manufacturer, Janssen Pharmaceuticals, failed to adequately warn consumers of the risks associated with the drug.

Recent studies have now shown Invokana can cause a life-threatening condition called Ketoacidosis, which occurs when the body overproduces ketones (or acid causing blood toxicity. In addition to ketoacidosis, Invokana increases a patient’s likelihood of amputation and can also permanently damage the kidneys.

Earlier this month, a plaintiff from New York filed a motion with the U.S. Judicial Penal on Multidistrict Litigation to consolidate federal claims in the litigation to the U.S. District Court of New Jersey. However, plaintiffs in Philadelphia have also filed a motion for consolidation, suggesting a mass tort program.

The consolidation could have profound implications. Hundreds of lawsuits have been filed in both federal and state courts across the country, and it is anticipated the litigation will continue to grow.

Earlier this week, Janssen received FDA approval for Invokamet XR, another diabetes drug similar to Invokana. Invokamet XR is being touted as a superior alternative, but if the company is hoping to put its Invokana days behind them, it’s out of luck.

Both the FDA and Health Canada have issued warnings regarding Invokana and the European Medicines Agency has even asked doctors to consider taking patients off Invokana.

Janssen has a lot at stake with the Ivokana litigation. The drug brought in approximately $1 billion in sales in 2015 alone. Janssen is trying to remove some of the cases filed in the Pennsylvania state court and are also using a federal preemption rule to throw out state cases. While Janssen is trying to mitigate Invokana lawsuits, plaintiffs aren’t going down without a fight.